Zynerba Pharmaceuticals, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • July 23rd, 2015 • Zynerba Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Introductory. Zynerba Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of [·] shares of its common stock, par value $0.001 per share (the “Shares”). The [·] Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional [·] Shares as provided in Section 2. The additional [·] Shares to be sold by the Company pursuant to such option are called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Jefferies LLC (“Jefferies”) and Piper Jaffray & Co. (“Piper Jaffray”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To the extent there are no addition
ZYNERBA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • July 23rd, 2015 • Zynerba Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is effective as of , by and between Zynerba Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Zynerba”), and (“Indemnitee”).
